Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group-Reference-Cited by-同舟云学术

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group

Published:2015-04 Issue:4 Volume:21 Page:653-660
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Schroeder Thomas,Rachlis Elena,Bug Gesine,Stelljes Matthias,Klein Stefan,Steckel Nina Kristin,Wolf Dominik,Ringhoffer Mark,Czibere Akos,Nachtkamp Kathrin,Dienst Ariane,Kondakci Mustafa,Stadler Michael,Platzbecker Uwe,Uharek Lutz,Luft Thomas,Fenk Roland,Germing Ulrich,Bornhäuser Martin,Kröger Nicolaus,Beelen Dietrich W.,Haas Rainer,Kobbe Guido

Funder

Celgene

Hospira

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference30 articles.

1. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation

2. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation

3. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation;Porter;Biol Blood Marrow Transplant,2010

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

5. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia;Fenaux;J Clin Oncol,2010

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WT1 Expression Is Associated with Poor Overall Survival after Azacytidine and DLI in a Cohort of Adult AML and MDS Patients;Cancers;2024-09-04

2. Dynamic Relapse Prediction by Peripheral Blood WT1mRNA after Allogeneic Hematopoietic Cell Transplantation for Myeloid Neoplasms;Transplantation and Cellular Therapy;2024-08

3. Monitoring molecular changes in the management of myelodysplastic syndromes;British Journal of Haematology;2024-06-27

4. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia;International Journal of Hematology;2024-05-25

5. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies;Bone Marrow Transplantation;2024-05-23